Business
NeuroPace Reports First Quarter 2025 Financial Results
-- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million -- -- On track to announce topline data from the NAUTILUS pivotal study in the second half of 2025 -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on
About this update from Neuropace, Inc.
[{"type":"image","alt":"NeuroPace, Inc.","displaySize":"","headline":null,"caption":"NeuroPace, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":52,"url":"https://media.zenfs.com/en/globenewswire.com/49cad5934d5ea78febfb7e12e9a6509b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5Q0OXhSfgqHpvUIbwQZadQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTczO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/49cad5934d5ea78febfb7e12e9a6509b","width":300,"height":52}},"lazy":false},{"type":"text","content":"-- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products --","length":132,"tagName":"p"},{"type":"text","content":"-- Increased full-year 2025 revenue guidance to $93 to $97 million --","length":69,"tagName":"p"},{"type":"text","content":"-- On track to announce topline data from the NAUTILUS pivotal study in the second half of 2025 --","length":98,"tagName":"p"},{"type":"text","content":"-- Management scheduled to host a conference call today at 4:30 p.m. ET --","length":74,"tagName":"p"},{"type":"text","content":"MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.","length":288,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue grew 24% year-over-year to $22.5 million in the first quarter of 2025","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"RNS System revenue grew 26% year-over-year in the first quarter of 2025, or 29% when excluding revenue from implants in the NAUTILUS study in the first quarter of 2024","length":167,"tagName":"p"}]},{"val":[{"type":"text","content":"Delivered strong gross margin of 77.0% in the first quarter of 2025, exceeding the top end of the Company’s full year guidance range","length":132,"tagName":"p"}]},{"val":[{"type":"text","content":"Demonstrated ongoing operating leverage with operating expenses growing 8% year-over-year despite the increase in revenue in the first quarter of 2025","length":150,"tagName":"p"}]},{"val":[{"type":"text","content":"Built on Project CA...